Table 1 Clinicopathologic features of all patients (cases (%))

Gender

0.001*

Male/Female

61(47.7)/67(52.3)

32(76.2)/10(23.8)

Age(yr)

0.001*

≤ 60/> 60

75(58.6)/53(41.4)

12(28.6)/30(71.4)

Tumor location

Upper

61(47.7)

14(33.3)

Middle

45(35.2)

20(47.6)

Lower

22(17.2)

8(19.0)

Greatest tumor diameter (cm)

0.000*

≤ 2

19(14.8)

35(83.3)

From >2 to 5

69(53.9)

7(16.7)

From >5 to 10

24(18.8)

0(0.0)

>10

16(12.5)

0(0.0)

Tumor bleeding

Yes/No

15(11.7)/113(88.3)

1(2.4)/41(97.6)

Tumor ulceration

0.014*

Yes/No

36(28.6)/92(71.4)

4(9.5)/38(90.5)

Mitotic count

≤ 5/50 HPF

97(75.8)

38(90.5)

From >5 to 10/50 HPF

21(16.4)

3(7.1)

>10/50 HPF

10(7.8)

1(2.4)

Risk stratification

0.000*

Very low

17(13.3)

35(83.3)

Low

54(42.2)

4(9.5)

Intermediate

27(21.1)

2(4.8)

High

30(23.4)

1(2.4)

Tumor necrosis

Yes/No

7(5.5)/121(94.5)

1(2.4)/41(97.6)

Cystic tumor

Yes/No

10(.8)/118(92.2)

0(0.0)/42(100.0)

CD117

0.009*

(−)/(+)

19(14.8)/109(85.2)

14(33.3)/28(66.7)

CD34

0.000*

(−)/(+)

11(8.6)/117(91.4)

17(40.5)/25(59.5)

SMA

(−)/(+)

82(64.1)/46(35.9)

30(71.4)/12(28.6)

S-100

(−)/(+)

116(90.6)/12(9.4)

38(90.5)/4(9.5)

Postoperative complications

Yes/No

18(14.1)/110(85.9)

9(21.4)/33(78.6)